347 related articles for article (PubMed ID: 27070731)
1. The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.
Palomino JC; Martin A
Future Microbiol; 2016; 11(4):539-47. PubMed ID: 27070731
[TBL] [Abstract][Full Text] [Related]
2. Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Schön T; Simonsson US; Bruchfeld J; Larsson M; Juréen P; Sturegård E; Giske CG; Ängeby K
Antimicrob Agents Chemother; 2014 Dec; 58(12):7557-9. PubMed ID: 25246405
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis.
Alsaad N; van Altena R; Pranger AD; van Soolingen D; de Lange WC; van der Werf TS; Kosterink JG; Alffenaar JW
Eur Respir J; 2013 Aug; 42(2):504-12. PubMed ID: 23100498
[TBL] [Abstract][Full Text] [Related]
4. Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis.
Ogwang S; Good CE; Okware B; Nsereko M; Jacobs MR; Boom WH; Bark CM
Antimicrob Agents Chemother; 2015 Sep; 59(9):5844-6. PubMed ID: 26169400
[TBL] [Abstract][Full Text] [Related]
5. Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection.
Rodrigues-Junior VS; Villela AD; Gonçalves RS; Abbadi BL; Trindade RV; López-Gavín A; Tudó G; González-Martín J; Basso LA; de Souza MV; Campos MM; Santos DS
Int J Antimicrob Agents; 2016 Aug; 48(2):203-7. PubMed ID: 27364701
[TBL] [Abstract][Full Text] [Related]
6. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
7. Multidrug-resistant tuberculosis: treatment is empirical, for want of robust trials.
Prescrire Int; 2014 Oct; 23(153):245-6. PubMed ID: 25964976
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
9. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
10. [Management of multidrug-resistant tuberculosis].
Tritar F; Daghfous H; Ben Saad S; Slim-Saidi L
Rev Pneumol Clin; 2015; 71(2-3):130-9. PubMed ID: 25153927
[TBL] [Abstract][Full Text] [Related]
11. Resistance patterns of multidrug-resistant tuberculosis in Western Province, Papua New Guinea.
Simpson G; Coulter C; Weston J; Knight T; Carter R; Vincent S; Robertus L; Konstantinos A
Int J Tuberc Lung Dis; 2011 Apr; 15(4):551-2. PubMed ID: 21396218
[TBL] [Abstract][Full Text] [Related]
12. Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis.
Alsaad N; Wilffert B; van Altena R; de Lange WC; van der Werf TS; Kosterink JG; Alffenaar JW
Eur Respir J; 2014 Mar; 43(3):884-97. PubMed ID: 23988774
[TBL] [Abstract][Full Text] [Related]
13. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
Migliori GB; Lange C; Girardi E; Centis R; Besozzi G; Kliiman K; Ortmann J; Matteelli A; Spanevello A; Cirillo DM;
Clin Infect Dis; 2008 Mar; 46(6):958-9. PubMed ID: 18288911
[No Abstract] [Full Text] [Related]
14. Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.
Kempker RR; Kipiani M; Mirtskhulava V; Tukvadze N; Magee MJ; Blumberg HM
Emerg Infect Dis; 2015 Jun; 21(6):992-1001. PubMed ID: 25993036
[TBL] [Abstract][Full Text] [Related]
15. Resistance to anti-tuberculosis medications in the Horn of Africa.
Ollé-Goig JE; Codina-Grau G; Martín-Casabona N
Int J Tuberc Lung Dis; 2011 Mar; 15(3):414-6. PubMed ID: 21333114
[TBL] [Abstract][Full Text] [Related]
16. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
Palomino JC; Martin A
Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
[TBL] [Abstract][Full Text] [Related]
18. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?
Yew WW; Koh WJ
Korean J Intern Med; 2016 Jan; 31(1):15-29. PubMed ID: 26767853
[TBL] [Abstract][Full Text] [Related]
19. Management of multidrug resistant tuberculosis.
Daley CL; Caminero JA
Semin Respir Crit Care Med; 2013 Feb; 34(1):44-59. PubMed ID: 23460005
[TBL] [Abstract][Full Text] [Related]
20. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
